Axovant reaps the rewards from its gene therapy refocus
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.
Death of a unicorn
Moderna’s upsized IPO is the biggest-ever for a pre-commercial biotech. But its share price has fallen in early trade on its first day.
Biotech flotations remain in high demand
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
Most valuable unpartnered assets reveal a changing of the guard
Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
Not developing your gene therapy? Call Axovant
Axovant's need to rebuild its pipeline is benefiting gene therapy developers.
Axovant looks to Oxford Biomedica for gene therapy resurrection
Axovant transforms itself into a new gene therapy company with an old Oxford Biomedica product.
Where is the IPO class of 2014-15 now?
A golden age for biotech flotations yielded some spectacular blow-ups, but also saw several groups reward investors with premium-priced takeovers.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.